Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease

NCT04055818 is registered in ClinicalTrials.gov with EpiDestiny, Inc. as lead sponsor.

NCT NCT04055818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease
Lead sponsor
EpiDestiny, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 24, 2020
Completion date
January 20, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease